Anesth Essays Res:下肢手术中蛛网膜下腔注射常规剂量不同浓度的低比重左旋布比卡因的对比研究

2017-11-13 周倩 罂粟花

背景与目的:低比重脊髓麻醉对于单侧下肢骨折是有利的,因为它可以消除躺下后由骨折肢体受压后导致的蛛网膜下腔阻滞而引起的疼痛。本研究比较了三种常规剂量不同浓度的低比重左布比卡因的阻滞特征和并发症,以确定选用左布比卡因的最佳浓度。

背景与目的:低比重脊髓麻醉对于单侧下肢骨折是有利的,因为它可以消除躺下后由骨折肢体受压后导致的蛛网膜下腔阻滞而引起的疼痛。本研究比较了三种常规剂量不同浓度的低比重左布比卡因的阻滞特征和并发症,以确定选用左布比卡因的最佳浓度。

方法:120美国麻醉医师学会:将纳入的18-65岁的单侧下肢手术患者分为三组,进行前瞻性群组研究。将0.4mL、0.6mL和0.8mL的蒸馏水分别加入ABC三组的2mL0.5%等比重的左布比卡因(10mg)溶液中,ABC三组得到的左布比卡因浓度分别为0.999294、0.998945和0.998806。通过针刺法和Bromage量表评估感觉和运动的阻滞情况,并记录痛觉缺失和并发症的总持续时间。利用平均值、标准误差、单因素方差分析和Bonferroni来分析定量变量;利用比例和卡方检验分析定性变量。

结果:从人口统计学参数、肢体运动阻滞和并发症几个方面进行比较。C组的感觉阻滞开始得最快(10.10分钟),痛觉缺失的持续时间最长(478.97分钟;P <0.001);但感觉水平较高(48.7%)。 B组的T10感觉水平为92.5%;感觉阻滞开始时间与C组相当(P = 0.248),痛觉缺失的持续时间合理(332.50分钟)。A组的感觉水平偏低,感觉阻滞开始得迟缓且很快消失。

结论:比起另外两组,B组(浓度:0.998945)有较好的阻滞特征。

原始出处:

Biji KP, Sunil M, Ramadas KT.Comparative Study of Constant Dose Intrathecal Hypobaric Levobupivacaine with Varying Baricities in Lower Limb Surgeries.Anesth Essays Res. 2017 Jul-Sep;11(3):642-646.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2050904, encodeId=271a2050904fe, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 19 18:00:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654447, encodeId=6d0c165444e48, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Thu Mar 08 08:00:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544485, encodeId=2cb4154448532, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Nov 15 02:00:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545966, encodeId=2a9e15459663a, content=<a href='/topic/show?id=5d4a48412f1' target=_blank style='color:#2F92EE;'>#布比卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48412, encryptionId=5d4a48412f1, topicName=布比卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=321313846448, createdName=12498c32m72暂无昵称, createdTime=Wed Nov 15 02:00:00 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2050904, encodeId=271a2050904fe, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 19 18:00:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654447, encodeId=6d0c165444e48, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Thu Mar 08 08:00:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544485, encodeId=2cb4154448532, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Nov 15 02:00:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545966, encodeId=2a9e15459663a, content=<a href='/topic/show?id=5d4a48412f1' target=_blank style='color:#2F92EE;'>#布比卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48412, encryptionId=5d4a48412f1, topicName=布比卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=321313846448, createdName=12498c32m72暂无昵称, createdTime=Wed Nov 15 02:00:00 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2050904, encodeId=271a2050904fe, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 19 18:00:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654447, encodeId=6d0c165444e48, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Thu Mar 08 08:00:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544485, encodeId=2cb4154448532, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Nov 15 02:00:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545966, encodeId=2a9e15459663a, content=<a href='/topic/show?id=5d4a48412f1' target=_blank style='color:#2F92EE;'>#布比卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48412, encryptionId=5d4a48412f1, topicName=布比卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=321313846448, createdName=12498c32m72暂无昵称, createdTime=Wed Nov 15 02:00:00 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2050904, encodeId=271a2050904fe, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 19 18:00:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654447, encodeId=6d0c165444e48, content=<a href='/topic/show?id=5ab788e81d3' target=_blank style='color:#2F92EE;'>#蛛网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88781, encryptionId=5ab788e81d3, topicName=蛛网膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=396c24497244, createdName=aliceclz, createdTime=Thu Mar 08 08:00:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544485, encodeId=2cb4154448532, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Nov 15 02:00:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545966, encodeId=2a9e15459663a, content=<a href='/topic/show?id=5d4a48412f1' target=_blank style='color:#2F92EE;'>#布比卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48412, encryptionId=5d4a48412f1, topicName=布比卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=321313846448, createdName=12498c32m72暂无昵称, createdTime=Wed Nov 15 02:00:00 CST 2017, time=2017-11-15, status=1, ipAttribution=)]

相关资讯

Medicine :臂丛神经阻滞,左布比卡因和罗哌卡因的术后镇痛效果并无差异

在药物的基础上,一般认为左布比卡因较罗哌卡因可持续更长的时间。然而,大多数报告臂丛阻滞时这两种麻醉剂在镇痛效果上并未存在明显的差异。本研究旨在对比左布比卡因和罗哌卡因用于治疗超声引导下臂丛神经阻滞术后的镇痛效果。 研究共纳入62名接受骨科手术的患者,随机接受左布比卡因( L组、n = 31)或罗哌卡因(R组,n = 31  )。记录患者术后镇痛持续时间、运动阻滞偏移时间、术后镇痛药用量及术后